Liarozole: A Novel Treatment Approach for Advanced Prostate Cancer - Results of a Large Randomized Trial Versus Cyproterone Acetate

    July 1998 in “ Urology ”
    F. Debruyne, Robin Murray, Yves Fradet … Peter De Porre
    Studysummary This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on goldjournal.net →
    Discuss this study in the Community →